

EU Technical Documentation Assessment Certificate Medical Device Regulation 2017/745

The National Standards Authority of Ireland (NSAI) as a duly designated Notified Body, (identification number 0050) for the purposes of the European Union under MDR 2017/745

HAS ASSESSED THE TECHNICAL DOCUMENTATION SUBMITTED BY

Becton, Dickinson and Company

1 Becton Drive Franklin Lakes, NJ 07417, USA

Manufacturer SRN: US-MF-000019182

Becton Dickinson Ireland Ltd.

Authorised Representative Name and

Address:

Donore Road County Louth

Drogheda, A92 YW26, Ireland

BD PosiFlush™ syringes Scope:

> BD PosiFlush™ XS Syringes are intended to be used FOR FLUSHING ONLY of in-situ peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs), central venous

catheters (CVCs), and implanted venous access ports.

BD PosiFlush™ XS Syringe is not intended for dry product reconstitution, for medication dilution,

or where intravenous therapy with sodium chloride is indicated.

Intended

Using aseptic technique, BD PosiFlush™ XS Syringe can be used on a sterile field.

Purpose

BD PosiFlush™ SP Syringes are intended to be used FOR FLUSHING ONLY of in-situ peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs), central venous

catheters (CVCs), and implanted venous access ports.

BD PosiFlush™ SP Syringe is not intended for dry product reconstitution, for medication dilution,

or where intravenous therapy with sodium chloride is indicated.

BD PosiFlush™ SP Syringe must not be used on a sterile field.

Conclusion: Technical documentation complies with the requirements of Annex IX, Chapter II (where applicable with Section 5.1) of MDR 2017/745.

Product Certificate Number: Re-Issued Date: 745.008D

21 December First Issue Date:

2022

Expiry Date:

20 December 2027

Site Certificate Number: MD19.2305

Signed:

Approved by:

Lisa Donlon

European Medical Device Operations Manager

Approved by: Dr Majella Geraghty

European Medical Device Operations Manager

MCT-3007 Rev 2.0 CERT-270 Page 1 of 4 CONDITIONS AND LIMITATIONS: This certificate remains valid on condition that the Approved Quality Management System is maintained in an adequate and efficacious manner in line with the requirements of the Regulation and shall be subject to surveillance audits carried out by the Notified Body. This certificate is based on examination of identified relevant CS, harmonised standards, test reports and audit reports maintained on file with NSAI. Information on examination and tests as per Annex XII, section 10, is available on request. Changes which could affect conformity with the General Safety and Performance Requirements of MDR 2017/745 or with the conditions prescribed for use of the product must receive further approval from NSAI.

The validity of this certificate depends on conditions and/or is limited to the following:

National Standards Authority of Ireland, 1 Swift Square, Northwood, Santry, Dublin 9, Ireland.

MCT-3007 Rev 2.0 CERT-270 Page 2 of 4

| Appendix I | | | | | | |
|--------------------------------|------------------|--|------------|--|--|--|
| Devices Covered by Certificate | | | | | | |
| Model Number | Basic UDI-DI | Description | Risk Class | | | |
| 306573 | 038290WKCQDZQWJK | BD PosiFlush™ SP Syringes 3ml | Ш | | | |
| 306583 | 038290WKCQDZQWJK | BD PosiFlush™ SP Syringes 3ml EMA/CIS | Ш | | | |
| 30657371 | 038290WKCQDZQWJK | BD PosiFlush™ SP Syringes 3ml India | Ш | | | |
| 306574 | 038290WKCQDZQWJK | BD PosiFlush™ SP Syringes 5ml | III | | | |
| 306584 | 038290WKCQDZQWJK | BD PosiFlush™ SP Syringes 5ml EMA/CIS | 111 | | | |
| 30657471 | 038290WKCQDZQWJK | BD PosiFlush™ SP Syringes 5ml India | III | | | |
| 306575 | 038290WKCQDZQWJK | BD PosiFlush™ SP Syringes 10ml | III | | | |
| 306585 | 038290WKCQDZQWJK | BD PosiFlush™ SP Syringes 10ml EMA/CIS | III | | | |
| 30657571 | 038290WKCQDZQWJK | BD PosiFlush™ SP Syringes 10ml India | III | | | |
| 306570 | 038290WKCQDZQWJK | BD PosiFlush™ XS Syringes 3ml | Ш | | | |
| 306580 | 038290WKCQDZQWJK | BD PosiFlush™ XS Syringes 3ml EMA/CIS | Ш | | | |
| 306571 | 038290WKCQDZQWJK | BD PosiFlush™ XS Syringes 5ml | Ш | | | |
| 306581 | 038290WKCQDZQWJK | BD PosiFlush™ XS Syringes 5ml EMA/CIS | III | | | |
| 306572 | 038290WKCQDZQWJK | BD PosiFlush™ XS Syringes 10ml | Ш | | | |
| 306582 | 038290WKCQDZQWJK | BD PosiFlush™ XS Syringes 10ml EMA/CIS | 111 | | | |

| Appendix II | | | | | | |
|-------------------------------|---------------|--|-------------------|--|--|--|
| Certificate History | | | | | | |
| Product Certificate Number | Date of Issue | Type of Change [supplemented, modified or re-issued] | Details of Change | | | |
| n/a | n/a | n/a | n/a | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |



EU Quality Management System Certificate

Medical Device Regulation 2017/745

The National Standards Authority of Ireland as a duly designated Notified Body, (0050) for the purposes of the European Union under MDR 2017/745

APPROVES THE QUALITY MANAGEMENT SYSTEM APPLIED BY

Becton, Dickinson and Company 1 Becton Drive Franklin Lakes, NJ 07417, USA

Manufacturer SRN: US-MF-000019182

Becton Dickinson Ireland Ltd.

Authorised Representative Donore Road Name and Address: County Louth

Drogheda, A92 YW26, Ireland

Device Group: BD PosiFlush™ syringes

Risk Class:

The BD PosiFlush™ XS Syringes are intended to be used FOR FLUSHING ONLY of in-situ peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs), central venous catheters (CVCs), and implanted venous access ports.

central verious catrieters (CVCs), and implanted verious access ports.

BD PosiFlush™ XS Syringe is not intended for dry product reconstitution, for medication

dilution, or where intravenous therapy with sodium chloride is indicated.

Intended Purpose

Using aseptic technique, BD PosiFlush™ XS Syringe can be used on a sterile field.

The BD PosiFlush™ SP Syringes are intended to be used FOR FLUSHING ONLY of in-situ peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs),

central venous catheters (CVCs), and implanted venous access ports.

BD PosiFlush™ SP Syringe is not intended for dry product reconstitution, for medication

dilution, or where intravenous therapy with sodium chloride is indicated.

BD PosiFlush™ SP Syringe must not be used on a sterile field.

Conclusion: Quality Management System complies with the requirements of Annex IX, Chapter I & III of MDR 2017/745. The use of the NSAI Notified Body Identification Number 0050 in conjunction with CE Marking of Conformance for this product is hereby authorised.

Product Certificate Number: 745.008 Re-Issued Date:

First Issue Date: 21 December 2022 Expiry Date: 20 December 2027

Site Certificate Number: MD19.2305

Signed:

Approved by: Lisa Donlon

European Medical Device Operations Manager

Approved by: Dr Majella Geraghty

European Medical Device Operations Manager

MCT-3005 Rev 2.0 CERT-281 Page 1 of 3

CONDITIONS AND LIMITATIONS: this certificate remains valid on condition that the Approved Quality Management System is maintained in an adequate and efficacious manner in line with the requirements of the Regulation. This certificate is based on examination of identified relevant CS, harmonised standards, test reports and audit reports maintained on file with NSAI. Information on examination and tests as per Annex XII, section 10, is available on request. Details of the current product range and operational locations included within the scope of this approval can be obtained from NSAI. Substantial Changes to the QMS or the product range covered must receive further approval from NSAI.

The validity of this certificate depends on conditions and/or is limited to the following:

National Standards Authority of Ireland, 1 Swift Square, Northwood, Santry, Dublin 9, Ireland.

MCT-3005 Rev 2.0 CERT-281 Page 2 of 3

| Appendix I | | | | | | |
|-------------------------------|---------------|---|-------------------|--|--|--|
| Certificate History | | | | | | |
| Product Certificate Number | Date of Issue | Type of Change [supplemented, modified or reissued] | Details of Change | | | |
| n/a | n/a | n/a | n/a | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

MCT-3005 Rev 2.0 CERT-281 Page 3 of 3